Serum parathyroid hormone (PTH) levels have been measured in 8 patients with hypercalcaemia associated with urological malignancy:. 3 renal cell carcinomas, 2 adenocarcinomas of prostate, 2 transitional cell carcinomas of bladder and one transitional cell carcinoma of kidney. Five (63%) of these 8 patients had bone metastases. PTH was detectable in the serum of all 8 hypercalcaemic patients, but in only 2 cases was the PTH level above the normal range, and in one of these a coincidental parathyroid adenoma was found to be responsible for the hypercalcaemia. It appears that these tumours can produce a hormone-like substance with biological effects similar to PTH.
Introduction
Hypercalcaemia associated with malignant disease is best described as a paraneoplastic syndrome. It is becoming evident that cancer cells are totipotential in their ability to produce hormone-like substances with clinical effects similar to true endocrine' hyperfunction. The term 'ectopic hormone production' is best avoided because it implies that the tumour is producing the same substance that would be elaborated by endocrine glands under normal circumstances. The clinical v'alue of PTH estimation in malignant hypercalcaemia therefore requires careful consideration.
In malignant disease hypercalcaemia is equally common in patients with and without osseous metastases', indicating that hypercalcaemia is not only related to metastatic osteolysis. This implies that the hypercalcaemia will not be altered by local Table 1 . Urological malignant disease associated with hypercalc treatment of metastatic disease, but requires more general treatment of the malignant process.
In order to clarify the relationship between serum PTH levels, osseous metastases and hypercalcaemia associated with urological malignancy, we have studied 8 patients in detail, only 5 of whom had evidence of metastases in bone.
Paper read to Section of Urology, 24 May 1985 Patients and methods Hypercalcaemia has been observed in 11 patients with malignant urological disease. There were 6 cases of renal cell carcinoma, 2 cases of adenocarcinoma of the prostate, 2 cases of transitional cell carcinoma of the' bladder and a single case of renal transitional cell carcinoma. However, 3 of the 11 cases who werelterminally ill with severe hypercalcaemia and osseous metastases did not undergo PTH estimation and' are therefore excluded from this study. The salient features of the remaining 8 cases are recorded in Table 1 . Serum PTH was measured by radioimmunoassay. Serum calcium estimations were made from fasting unoccluded serum samples and were corrected for a serum albumin of 47'mmol/l. Osseous metastases were diagnosed by isotope bone scan, and confinned by plain radiographs in equivocal cases. Five of 8 patients had unequivocal scintigraphic evidence of widespread osseous metastases.
Results
Six out of 8 patients had serum PTH levels within the normal range: one of 2 patients with elevated levels of PTH was shown to have a secreting parathyroid adenoma by-selective venous sampling; the diagnosis was confirmed by neck exploration, and this patient remains well 4 years later. Only 7 patients, therefore, had hypercalcaemia directly due to malignant urological disease. Serum calcium responded to treatment of the primary tumour in 6 cases, and this response did not seem to be dependent on the presence or absence of osseous metastases. For example, Figure 1 depicts the relationship of serum calcium, serum phosphate and serum PTH in a patient presenting with renal cell carcinoma and a corrected serum calcium of 2.69 mmol/L This patient, despite the presence of osseous metastases, enjoyed a symptom-free interval of one year following tumour nephrectomy. However, extension of the widespread metastatic disease was associated with recurrent hypercalcaemia only poorly controlled by steroid therapy.
Discussion PTH assay has revealed normal hormone levels in 75% of our patients with urological tumours and hypercalcaemia; in 2 cases the PTH level was in the hyperparathyroid range, but in only one case was there any evidence of parathyroid disease. The humoral mediation ofhypercalcaemia in the remaining cases was therefore by a substance which did not crossreact in the radioimmunoassay for normal PTH. Thus PTH estimation appears to be of use only when urological malignancy, hypercalcaemia and hyperparathyroidism coexist. In our case, selective venous sampling for PTH indicated the hyperparathyroid production of excess normal hormone. The realization that hypercalcaemia may be associated with malignant disease of non-parathyroid origin was stimulated by unrewarding neck exploration in patients with urological neoplasms2. The incorrect assumption that such hypercalcaemia was due only to the osteolysis caused by bone metastases can now be corrected by clinical evidence. Thus non-metastatic tumours produce hypercalcaemia, and hypercalcaemia is equally common in patients with and without bony metastases; and when osteo-clastic osteolysis causes a raised serum calcium, physiological negative feedback should stimulate a state ofhypoparathyroidism rather than the reverse.
The osteoblast is central to the genesis of hypercalcaemia in non-metastatic malignant disease. It seems that a PTH-like humoral mediator stimulates the osteoblast which in turn stimulates osteoclastic activity3. Osteoclast activating factor (OAF) and prostaglandin E2 (PGE2) have been suggested as the tumour-produced mediators of hypercalcaemia4. Both OAF and PGE2 are produced by tumour cells, and the possibility of treating malignant hypercalcaemia with prostaglandin synthetase inhibitors has been suggested5. Our own experience of the use of non-steroidal anti-inflammatory drugs in this context coincides with other reports6 which showed that the hypercalcaemia of malignant disease was not responsive to treatment with indomethacin. The treatment of hypercalcaemia of malignant disease should therefore be directed at the tumour itself to reduce the production of PTH hormone-like mediators. Treatment directed towards a reduction in bone metabolism is at present less successful. A second PTH-like activity which may derive from tumour-produced substances is an increase in tubular reabsorption of calcium'. The development of specific parathyroid hormone antagonists7 might provide a new therapeutic approach to the renotropic effects in malignant hypercalcaemia.
The practical value of serum calcium estimation in all patients with urological malignancy is twofold: specific treatment improves the clinical state, even in terminal disease, and preoperative hypercalcaemia provides a useful tumour marker. Thus, depression, lassitude, anorexia and constipation may be directly attributable to hypercalcaemia and yet give the clinical impression of terminal disease. Steroid therapy (20mg enteric-coated prednisolone per day) provides great symptomatic benefit even with advanced disease. However, in -3 of our cases the serum calcium was below 3.0 mmol/l and was not symptomatic. The serum calcium level in these cases provided an accurate tumour marker. Hypercalcaemia is a common effect of urological malignancy. Therapy is possible and should be directed to the primary tumour, even in the presence of metastases. Tumour-produced substances are the mediators of the hypercalcaemia which was previously thought to be due to ectopic parathyroid hormone production. Identification of the exact mediator of this common paraneoplastic syndrome will provide an excellent tumour marker. In the meantime, the estimation of serum calcium is a useful indicator of existing and recurrent disease, without the need for PTH estimation except in the case ofunsuspected, coexistent, parathyroid disease.
